Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.
Winnette R, Zárate V, Machnicki G, Demuro-Mercon C, Gawlicki M, Gnanasakthy A. Patient-reported outcomes in Latin America: implementation in research and role in emerging HTA systems. Value in Health Regional Issues. 2015 Dec;8:49-55. doi: 10.1016/j.vhri.2015.03.008
Hogue S, Hollis K, Silvia S, Wooddell M. The EpiPen4Schools® survey: staff training and use of epinephrine auto-injectors for the treatment of anaphylaxis in large US school districts. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. [abstract] Value in Health Regional Issues. 2015 Nov; 18(7):A505. doi: 10.1016/j.jval.2015.09.1441
Dalley C, Basarir H, Wright JG, Fernando M, Pearson D, Ward SE, Thokula P, Krishnankutty A, Wilson G, Dalton A, Talley P, Barnett D, Hughes D, Porter NR, Reilly JT, Snowden JA. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. J Clin Pathol. 2015 Apr;68(4):292-300. doi: 10.1136/jclinpath-2014-202624
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603